Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866107 | 0.92 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL19944669 | 0.89 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL29990821 | 0.87 | CYP2D6 (0.55) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL3689498 | 0.87 | CYP2D6 (0.55) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL168389 | 0.87 | CYP2D6 (0.55) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL344731 | 0.87 | CYP2D6 (0.55) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL18343731 | 0.86 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL19014943 | 0.85 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL16827590 | 0.85 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 | |
| SCHEMBL15905906 | 0.85 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CYP1A2 168/4885CYP2C9 154/4885CYP2C19 84/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CYP1A2 168/4885CYP2C9 154/4885CYP2C19 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.